Risk-benefit analysis of use of statins for primary prevention of cardiovascular disease in subjects without diabetes

Journal of Diabetes Investigation

Volumn 4, Issue 4, 2013, Pages 344-346

  Chan, Juliana Cn ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PITAVASTATIN; PLACEBO; ROSUVASTATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; LIFESTYLE MODIFICATION; NOTE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION;

EID: 84880174669     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12076     Document Type: Note

References (15)

1. Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-841.
2. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: 1769-1778.
3. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.
4. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2011; 375: 735-742.
5. Hopper I, Billah B, Skiba M, et al. Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials. Eur J Cardiovasc Prev Rehabil 2011; 18: 813-823.
6. Stirban AO, Tschoepe D. Should we be more aggressive in the therapy against cardiovascular risk factors? Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill? Diabetes Care 2008; 31(Suppl. 2): S226-S228.
7. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380: 565-571.
8. Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Curr Opin Cardiol 2011; 26: 342-347.
9. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009; 301: 2129-2140.
10. Chan JC, Chan SP, Deerochanawong C, et al. Diabetic dyslipidaemia in Asian populations in the Western Pacific Region: what we know and don't know. Diabetes Res Clin Pract 2011; 94: 1-13.
11. Luk AO, Yang X, Ma RC, et al. Association of statin use and development of renal dysfunction in type 2 diabetes-the Hong Kong Diabetes Registry. Diabetes Res Clin Pract 2010; 88: 227-233.
12. Inzucchi S, Sherwin R. The prevention of type 2 diabetes mellitus. Endocrinol Metab Clin North Am 2005; 34: 199-219.
13. Gong Q, Gregg EW, Wang J, et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia 2011; 54: 300-307.
14. Yamazaki T, Kishimoto J, Ito C, et al. Japan prevention trial of diabetes by pitavastatin in patients with impaired glucose tolerance (the J-PREDICT study): rationale, study design, and clinical characteristics of 1269 patients. Diabetol Int 2011; 2: 134-140.
15. Brown N, Critchley J, Bogowicz P, et al. Risk scores based on self-reported or available clinical data to detect undiagnosed Type 2 Diabetes: a systematic review. Diabetes Res Clin Pract 2012; 98: 369-385.